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Abstract
Mendelian randomization (MR) is an established approach to evaluate the effect of an
exposure on an outcome. The gene-by-environment (GxE) study design can be used to
determine whether the genetic instrument affects the outcome through pathways other
than via the exposure of interest (horizontal pleiotropy). MR phenome-wide association
studies (MR-pheWAS) search for the effects of an exposure, and can be conducted in UK
Biobank using the PHESANT package. In this proof-of-principle study, we introduce the
novel GxE MR-pheWAS approach, that combines MR-pheWAS with the use of GxE inter-
actions. This method aims to identify the presence of effects of an exposure while simulta-
neously investigating horizontal pleiotropy. We systematically test for the presence of
causal effects of smoking heaviness–stratifying on smoking status (ever versus never)–
as an exemplar. If a genetic variant is associated with smoking heaviness (but not smok-
ing initiation), and this variant affects an outcome (at least partially) via tobacco intake,
we would expect the effect of the variant on the outcome to differ in ever versus never
smokers. We used PHESANT to test for the presence of effects of smoking heaviness,
instrumented by genetic variant rs16969968, among never and ever smokers respec-
tively, in UK Biobank. We ranked results by the strength of interaction between ever and
never smokers. We replicated previously established effects of smoking heaviness,
including detrimental effects on lung function. Novel results included a detrimental effect
of heavier smoking on facial aging. We have demonstrated how GxE MR-pheWAS can be
used to identify potential effects of an exposure, while simultaneously assessing whether
results may be biased by horizontal pleiotropy.
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Author summary
Mendelian randomization uses genetic variants associated with an exposure to investigate
causality. For instance, a genetic variant that relates to how heavily a person smokes, has
been used to test whether smoking causally affects health outcomes. Mendelian randomi-
zation is biased if the genetic variant also affects the outcome via other pathways. We
exploit additional information–that the effect of heavy smoking only occurs in people
who actually smoke–to overcome this problem. By testing associations in ever and never
smokers separately we can assess whether the genetic variant affects an outcome via smok-
ing or another pathway. If the effect is at least partially via smoking heaviness, we would
expect the effect to differ in ever versus never smokers, and this would suggest that smok-
ing causally influences the outcome. Previous Mendelian randomization studies of smok-
ing heaviness focused on specific outcomes–here we searched for the presence of causal
effects of smoking heaviness across over 18 000 traits. We identified previously established
effects (e.g. a detrimental effect on lung function) and novel results including a detrimen-
tal effect of heavier smoking on facial aging. Our approach can be used to test for the pres-
ence of causal effects of other exposures, where the exposure only occurs in known
subsets of the population.
Introduction
Mendelian randomization (MR) is an established approach that uses genetic variants as prox-
ies for a modifiable exposure, to test for the presence of a causal effect of the exposure (or esti-
mate the magnitude of its effect) on a potential outcome [1]. MR is often implemented within
an instrumental variable (IV) framework, with a key assumption being that there is no alterna-
tive pathway between the genetic instrument and the outcome that is not via the exposure of
interest (exclusion restriction). Horizontal pleiotropy [2], where the genetic instrument affects
the outcome through pathways not via the exposure, invalidates this assumption. Whilst the
exclusion restriction cannot be statistically tested, MR studies can include an investigation of
evidence for a violation of this MR assumption [3]. For instance, where several independent
genetic instruments exist for an exposure, a difference in the effect estimates may indicate they
are acting through different pathways [4–6]. The majority of these approaches are only appli-
cable where there are several genetic variants that proxy for the exposure of interest [3,7].
A design in which the genetic variant is interacted with another variable can provide evi-
dence for violation of the exclusion restriction assumption. The additional variable can be of
many forms; not necessarily environmental. For example, an early study interacted a genetic
variant related to alcohol with sex in a population where women drank very little, such that an
effect of the variant on the outcome in women would suggest that at least some of the effect of
the variant on the outcome is not acting through alcohol consumption [8]. Here we report
interaction with another factor, and refer to the design henceforth as involving gene-by-envi-
ronment (GxE) interaction [8–12]. In contrast to traditional GxE studies that aim to identify
genetic variants whose effects on an outcome are modified by an environmental factor (or
vice-versa) [13], the aim here is to determine whether horizontal pleiotropy may be biasing
estimated causal effects [12]. To conduct a GxE MR study, a phenotype is chosen that stratifies
the population into two (or more) groups, with different levels of the exposure. In the ideal
case the exposure will manifest in one group but not in the other. If the effect of the genetic
variant is (at least partly) via the exposure, the estimate of the direct test between the genetic
variant and the outcome should vary in proportion to the degree the exposure manifests in
MR-pheWAS with stratification and interaction: Searching for the causal effects of smoking heaviness
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each group. Importantly, the genetic instrument should not be associated with the phenotype
used to stratify the sample, otherwise estimates may be biased due to conditioning on a collider
[14,15]. We also note that, while we focus on horizontal pleiotropy in this work, GxE MR can
be used to assess causal effects in the presence of other violations of the exclusion restriction as
long as this violation is the same across strata of the modifying factor (see for example S7 Fig).
The MR GxE approach has been used to investigate the effect of smoking heaviness on traits
such as body mass index (BMI) and depression/anxiety [16–21]. A causal effect of a genetic
variant known to affect smoking heaviness should, if the effect is solely via tobacco intake, be
seen in participants who are previous or current smokers, but not in participants who have
never smoked. Thus, by stratifying on smoking status (ever versus never), we can assess if the
smoking heaviness genetic variant is likely to be affecting an outcome via smoking heaviness,
or some other pathway (or both). Fig 1 illustrates the three broad types of results of a GxE
Fig 1. Illustration of possible GxE MR results and their interpretation. This figure illustrates the three broad types
of results of a GxE study on smoking heaviness: 1) no interaction between ever and never smokers, 2) a quantitative
interaction, where associations are in a consistent direction but one is stronger than the other, or 3) a qualitative
interaction, where the effect only occurs in one group or the estimates are in opposite directions, also known as a cross
over effect [22]. Both qualitative and quantitative interactions can provide evidence of a causal effect of the genetic
variant via smoking heaviness. However, when an effect exists in never smokers the estimate in ever smokers may be
comprised of both an effect of the genetic variant through smoking heaviness and an effect through another pathway.
https://doi.org/10.1371/journal.pgen.1008353.g001
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study on smoking heaviness: 1) no interaction between ever and never smokers, 2) a quantita-
tive interaction, where associations are in a consistent direction but one is stronger than the
other, or 3) a qualitative interaction, where the effect only occurs in one group or the estimates
are in opposite directions, also known as a cross over effect [22]. Both qualitative and quantita-
tive interactions can provide evidence of a causal effect of the genetic variant via smoking
heaviness. However, when an effect exists in never smokers the estimate in ever smokers may
be comprised of both an effect of the genetic variant through smoking heaviness and an effect
through another pathway.
While MR studies have, to date, been largely performed in a hypothesis-driven manner, it is
now possible to perform hypothesis-free MR analyses using the MR phenome-wide association
study (MR-pheWAS) approach [5,23]. MR-pheWAS search for the presence of causal effects
of an exposure of interest, by testing the direct effect of a genetic instrument on a potentially
large set of outcomes. We recently published a software package for performing comprehen-
sive phenome scans in UK Biobank called PHESANT [23]. PHESANT allows researchers to
systematically test the association of a trait of interest across over 22 000 phenotypes in UK
Biobank, and is the first freely-available tool for performing comprehensive phenome scans. In
this paper we combine this hypothesis-free approach with the use of GxE interactions in a
novel GxE MR-pheWAS approach. This method enables hypothesis-free searching for the
presence of causal effects of an exposure, while simultaneously assessing whether the genetic
instrument affects the outcome through other pathways (horizontal pleiotropy). In contrast to
hypothesis-driven GxE studies, our hypothesis-free study presented here is intended to be
hypothesis-generating–identifying potentially interesting associations to follow-up in indepen-
dent data. Our method provides evidence about which outcomes are likely to be caused by the
exposure, but does not attempt to estimate the magnitude of the identified causal effects. GxE
MR-pheWAS can be performed using the PHESANT software. We describe the methods we
have developed, compare different options for carrying out the analysis, and perform a proof
of principle study, searching for the effects of smoking heaviness. We then discuss the impor-
tant lessons raised by this first application of the approach.
Results
Each additional smoking-increasing allele of rs16969968 was associated with a 1.21 [95% con-
fidence interval (CI): 1.19, 1.23] higher odds of being in a higher smoking heaviness category,
after adjusting for age, sex and the first 10 genetic principal components, and a 0.98 [95% CI:
0.97, 0.99] lower odds of being an ever (vs never) smoker.
Results of GxE MR-pheWAS analysis
Identified interactions from GxE MR-pheWAS in ever smokers versus never smokers.
We performed a GxE MR-pheWAS analysis, ranking on the strength of the interaction
between ever versus never smokers (using the P value of Cochran’s Q-test statistic for hetero-
geneity). Of the 16 692 interactions tested, we identified 8 results with a P value lower than a
stringent Bonferroni corrected threshold of 3.00x10-6 (0.05/16 692), where an increase in
rs16969968 smoking-heaviness increasing allele dosage was associated with worse lung func-
tion (3 phenotypes), lower likelihood of being a morning person, and higher blood assay levels
(haematocrit percentage, white blood cell count, neutrophil count and haemoglobin concen-
tration) on average, in ever compared with never smokers. We found a further 4 results at a
false discovery rate of 5% (using a P value threshold of 0.05x12/16 692 = 3.59x10-5) (see S2
Table), where an increase in rs16969968 smoking-heaviness increasing allele dosage was asso-
ciated with a higher risk of chronic obstructive pulmonary disease, emphysema and cancer
MR-pheWAS with stratification and interaction: Searching for the causal effects of smoking heaviness
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diagnoses and greater facial aging, in ever compared with never smokers. A QQ plot is given
in Fig 2A.
Identified main effects from MR-pheWAS in ever smokers. While our main aim is to
identify interactions between the associations in ever versus never smokers (which may sug-
gest a causal effect via smoking heaviness), here we ranked outcomes by the strength of associ-
ation with rs16969968 in ever smokers to maximize statistical power. This approach relies on
the assumption that the combined effect through smoking heaviness and any horizontal pleio-
tropic effect is not null. For example, if the effects via smoking heaviness and a horizontally
pleiotropic pathway are of the same magnitude but in opposite directions then they would can-
cel out and not be identified in a MR-pheWAS in ever smokers. Under the assumption of no
horizontal pleiotropy a 5% FDR threshold on the strength of associations in ever smokers can
be used to control the proportion of ‘hits’ that are not due to an effect via smoking heaviness at
5%. However, if the effect of the genetic variant on some outcomes is horizontally pleiotropic
then this would inflate the FDR, such that the proportion of results below a 5% FDR P value
threshold that are not due to an effect via smoking heaviness may be higher than 5%.
The results of our MR-pheWAS among ever smokers includes 18 513 tests ranked by P
value of the estimated effect on each outcome, given in S1 File. A QQ plot is given in Fig 2B.
We identified 69 results at a false discovery rate of 5% (using a P value threshold of 0.05x69/18
513 = 1.86x10-4), given in Figs 3–5 and S3 Table, and of these, 32 results had a P value lower
than a stringent Bonferroni corrected threshold of 2.70x10-6 (0.05/18 513). For comparison,
we also performed MR-pheWAS among never smokers and in our full sample, and ranked
these results by the strength of association. We identified 8 results at a false discovery rate of
5% among never smokers (see S4 Table), and 48 results among our full sample (see S5 Table).
We also used a two-step approach to identify interactions, first ranking outcomes by the
Fig 2. QQ plots of PHESANT MR-pheWAS results. Green dashed: Bonferroni corrected threshold; Red dash-dotted: 5% false discovery rate (FDR) threshold; Blue
dotted: Expected = Actual; Purple points: results of tests performed: a) P-values of tests of interaction in GxE MR-pheWAS, and b) P-values of SNP-outcome
associations in MR-pheWAS among ever smokers. Multiple testing thresholds: a) Bonferroni threshold: 0.05/16692 = 3.00x10-6; 5% FDR threshold: 0.05x12/
16692 = 3.59x10-5, and b) Bonferroni threshold: 0.05/18513 = 2.70x10-6; 5% FDR threshold: 0.05x69/18513 = 1.86x10-4.
https://doi.org/10.1371/journal.pgen.1008353.g002
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strength of association in the whole sample and then ranking the 5% FDR ‘hits’ from the first
stage by the strength of interaction between ever and never smokers (P value of the Q-test sta-
tistic). This approach identified 9 results at a false discovery rate of 5% (see S6 Table).
The results identified (below the 5% FDR threshold) when ranking by our P value for inter-
action were a subset of those identified when ranking by the P value of the main effects among
ever smokers, except for a binary outcome describing whether the participant has had a kerati-
nizing squamous cell carcinoma (field ID [FID] = 40011, value 8071). A higher rs16969968
smoking-heaviness increasing allele dosage was associated with a higher risk of keratinizing
squamous cell carcinoma among ever smokers, but a lower risk among never smokers (such
that the strength of the interaction was stronger than the strength of the association in ever
smokers). Overlap of results across all our MR-pheWAS is shown in S1 Fig.
Detailed follow-up of potentially novel results. Our identified results from our GxE
MR-pheWAS (searching for interactions) included a detrimental effect of heavier smoking on
facial aging (FID = 1757), where a higher genetic predisposition to heavier smoking was associ-
ated with an increased risk of looking older (as perceived by others) relative to your age.
Fig 3. Identified main effects from MR-pheWAS in ever smokers, for binary outcomes. Results shown are those identified after correcting for multiple testing. 33 of
38 binary results are shown in this figure, with PHESANT binary result for never smokers. Results not shown in this figure are relevant to smoking participants only, e.g.
‘difficulty not smoking for 1 day’ such that they are absent in the never smokers (see S3 Table for further details).
https://doi.org/10.1371/journal.pgen.1008353.g003
MR-pheWAS with stratification and interaction: Searching for the causal effects of smoking heaviness
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Estimates of association of rs16969968 on facial aging are shown in Table 1. Among ever
smokers each additional smoking-increasing allele of rs16969968 was associated with a 1.062
[95% CI: 1.043, 1.081] higher odds of reporting an older facial aging category, and a 1.004
[95% CI: 0.988, 1.021] higher odds among never smokers (interaction P = 7.72x10-6). Our sen-
sitivity analyses adjusting for age, sex and the first 40 principal components were consistent
with the results of our main analyses.
We attempted to replicate this effect using a genetic risk score for lifetime smoking exposure,
a measure that incorporates duration of smoking and whether (and when) a person stopped
smoking, in addition to heaviness of smoking. A 1 standard deviation (SD) higher lifetime
smoking genetic instrument was associated with a 0.105 [95% confidence interval (CI): 0.102,
Fig 4. Identified main effects from MR-pheWAS in ever smokers, for continuous outcomes. Results shown are those identified after
correcting for multiple testing. 14 of 18 linear results are shown in this figure, with PHESANT linear result for never smokers. Results
not shown in this figure are relevant to smoking participants only, e.g. “amount of tobacco currently smoked” such that they are absent
in the never smokers (see S3 Table for further details).
https://doi.org/10.1371/journal.pgen.1008353.g004
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0.109] SD higher lifetime smoking score in our full sample, after adjusting for age, sex and the
first 10 genetic principal components. We estimated that a 1SD higher lifetime smoking score
caused a 1.293 [95% CI: 1.089, 1.534] higher odds of reporting that people say you look older
than you are, after adjusting for age, sex and the first 10 genetic principal components.
Testing the impact of collider bias. Our conclusions about the causal effect of smoking
heaviness on our outcomes may be affected by selection-induced collider bias [14,15]. This is
because we stratified on smoking status, and we found an effect of the smoking heaviness
genetic variant on smoking status. For instance, if any cause of an outcome also causes smok-
ing status, then an association may be induced between the smoking heaviness genetic variant
and that outcome (S2 Fig). If there is a true association between the genetic variant for smok-
ing heaviness and the outcome, then it could be estimated with bias in this scenario. We per-
formed a simulation to determine the degree of confounding needed to induce an association
Fig 5. Identified main effects from MR-pheWAS in ever smokers, for ordered categorical outcomes. Results shown
are those identified after correcting for multiple testing. 6 of 12 ordered categorical results are shown in this figure,
with PHESANT ordered categorical result for never smokers. Results not shown in this figure are predominantly
relevant to smoking participants only, e.g. “number of cigarettes smoked previously” such that they are absent in the
never smokers (see S3 Table for further details).
https://doi.org/10.1371/journal.pgen.1008353.g005
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between the genetic variant and our identified facial aging phenotype, given there is no true
causal effect of the SNP on the outcome. Further details of our simulation approach are given
in Section S1 in S1 Text. In brief, we assume rs16969968 affects smoking status to the extent
observed in UK Biobank and we assume a confounding variable affects both smoking status
and facial aging, which creates an alternate path between the SNP and the outcome via smok-
ing status when smoking status is conditioned on (S2 Fig). We simulate different strengths of
this confounding and assess the impact on the SNP-outcome associations. Our simulation
indicated that any collider bias due to the effect of the genetic variant on smoking status is
likely to have had a negligible impact on the estimated effect of the genetic variant on facial
aging (S3 Fig), given the same sample size and numbers of ever and never smokers as our UK
Biobank sample. For example, assuming no effect of rs16969968 on the outcome, and given a
confounder that is the only cause of facial aging and has a large effect on smoking status
(OR = 10), the estimated effect of rs16969968 on facial aging in ever and never smokers are
consistent and their confidence intervals both include the null. Hence, the degree of bias is not
sufficient to (incorrectly) suggest an effect of rs16969968 on facial aging via either smoking
heaviness or some other path.
The hypothesis-free nature of our analysis means that even when collider bias is small with
little impact on individual estimates, across many tests it is possible that this bias inflates the
false discovery rate–the proportion of ‘null’ results incorrectly identified as ‘hits’. We extended
the above simulation to investigate this assuming a phenome scan restricted to continuous
outcomes and found that inflation of the false discovery rate increased as the strength of the
colliding relationship increased (see Supplementary section S2 for further details). For exam-
ple, assuming no effect of the SNP on the outcomes, and given a confounder that has a large
effect on smoking status (OR = 100) and explains 20% of the variation in the outcomes, the
false discovery rate was 0.071.
Discussion
In this study, we searched for the presence of causal effects of smoking heaviness, using the
PHESANT software package to perform a GxE MR-pheWAS, by estimating the association of
Table 1. Results of associations of genetic instruments with facial aging outcome.
Analysis Sample N Odds ratio Interaction P value 3
Associations of rs16969968 on facial aging 1
Main analysis Ever smokers 137,869 1.062 [1.043, 1.081] 7.72x10-6
Never smokers 167,781 1.004 [0.988, 1.021]
Sensitivity analysis Ever smokers 137,869 1.062 [1.043, 1.081] 7.46x10-6
Never smokers 167,781 1.004 [0.988, 1.021]
Estimates of causal effect of lifetime smoking on facial aging 2
Main analysis Ever and never smokers 305,662 1.293 [1.089, 1.534] NA
Sensitivity analysis 1.294 [1.090, 1.536] NA
Main analysis: Adjusted for age, sex and first 10 genetic principal components. Sensitivity Analysis: Adjusted for age, sex and first 40 genetic principal components.
1 Direct test of association between smoking heaviness SNP and facial aging, in ever and never smokers separately. Estimates are the change of odds of reporting looking
‘older than you are’ versus looking ‘younger than you are’ or ‘about the same’, or looking ‘older than you are’ or ‘about the same’ versus ‘younger than you are’, for each
additional smoking-increasing allele of rs16969968.
2 Two stage IV probit regression. Estimates are the change of odds of reporting facial aging category ‘older than you are’ for a 1 SD increase in lifetime smoking score.
Calculated by taking the exponent of 1.6 times the probit estimate [24].
3 Interaction P value generated using meta regression (metan command in Stata).
https://doi.org/10.1371/journal.pgen.1008353.t001
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genetic variant rs16969968 with each outcome while restricting to ever and never smokers,
respectively. We used two approaches to identify potential causal effects of smoking heaviness
from our PHESANT results. Our main approach–the GxE MR-pheWAS–ranked results by the
strength of interaction between ever and never smokers. This approach is commensurate with
our aims, as a genetic variant that affects an outcome (at least in part) through smoking heavi-
ness will exhibit a different effect size on this outcome, among ever and never smokers, respec-
tively. However, identifying interactions has lower statistical power compared with identifying
a main effect, especially when combined with the need to correct for the multiple tests per-
formed in an MR-pheWAS. Our secondary approach ranked results based on the strength of
the effect of rs16969968 among ever smokers and identifies causal effects under the assump-
tion that the combined effect through smoking heaviness and any horizontal pleiotropic effect
is not null. For instance, given a positive effect of a genetic variant on an outcome via smoking
heaviness, and an equal but opposite effect via horizontal pleiotropy, then the effect of the vari-
ant would appear null in ever smokers and negative in never smokers, and hence this outcome
would not be identified when ranking by the effect among ever smokers. Under the assump-
tion of no horizontal pleiotropy a 5% FDR threshold would maintain the FDR of interactions
at 5% as well as the FDR of effects among ever smokers. However, the proportion of results
identified as a ‘hit’ among ever smokers, but for which there is no effect via smoking heaviness,
increases as the prevalence of horizontal pleiotropy increases.
Our GxE MR-pheWAS of smoking heaviness (ranking on interaction strength) identified
12 results, whereas our MR-pheWAS ranking on strength of effect in ever smokers identified
69 results. Of the 12 identified in the former, 11 of these were also identified in the latter. Fur-
thermore, the majority of results identified when ranking on the effect in ever smokers were
qualitative, with an effect seen among ever smokers but not among never smokers (type E in
Fig 1). Our results confirmed several established or previously reported causal effects of smok-
ing heaviness. For example, our findings suggested higher smoking heaviness was associated
with worse lung function (FIDs = {3063, 20150, 20154}) [25], higher risk of chronic obstructive
pulmonary disease (FID = 22130) [25] and skin cancer (FID = 40011 value 8071) [26], and
lower odds of being a morning person (FID = 1180) [27].
Our MR-pheWAS among ever smokers found only a weak negative effect of rs16969968 on
BMI that did not pass the 5% FDR threshold. Previous MR studies have also identified an effect
of smoking heaviness on BMI, where additional smoking-increasing alleles were associated
with a lower BMI among current smokers [10,16,20]. Since we used ever smokers rather than
current smokers our weaker association may be because the effect on BMI weakens over time
after smoking cessation [10]. Furthermore, while previous studies found an effect of
rs16969968 on BMI in never smokers [10,16,20], we found little evidence of an association in
UK Biobank.
We identified other novel results, including a detrimental effect of heavier smoking on
facial aging. We estimated that a 1SD increase in lifetime smoking causes a 1.29 [95% CI: 1.09,
1.53] higher odds of reporting that others say you look older than you are. A 1SD increase in
lifetime smoking is, for example, equivalent to being a current smoker who has smoked 5 ciga-
rettes per day for 12 years, or a former smoker who smoked 5 cigarettes per day for 21 years
but stopped smoking 10 years ago, rather than a never smoker. This identified association
should be further investigated and replicated in an independent sample, although at present
we are not aware of a study with sufficient sample size and data available to do this. Our identi-
fied association may reflect a true causal effect of smoking heaviness, may be due to chance, or
may arise because the genetic variants have horizontal pleiotropic effects and are thus invalid
instruments for smoking heaviness or lifetime smoking. However, we examined the extent to
which horizontal pleiotropy might be biasing our smoking heaviness results, by estimating the
MR-pheWAS with stratification and interaction: Searching for the causal effects of smoking heaviness
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effect of the smoking heaviness genetic variant among never smokers, and found little evidence
of an association, suggesting that smoking status modifies the effect of the genetic variant on
facial aging. This is consistent with an effect of the genetic variant via smoking heaviness, but
it is also possible that smoking status could modify a pathway from the genetic variant to facial
aging that is not via smoking heaviness (see S6 Fig and discussion of limitations below). It is
also possible that knowing a person’s smoking behavior might bias their perception of that per-
son’s facial aging. However, previous research does support an effect of smoking heaviness on
facial aging. For example, smoking has previously been associated with earlier facial wrinkling
[28]. Furthermore, a recent study assessed perceptions of facial attractiveness using a two-
alternative forced choice design where participants were randomly shown prototypical faces
for smokers and non-smokers and asked to select the most attractive, and found that smoking
faces were deemed less attractive [29]. Our study using MR is likely to have different sources of
potential biases such that triangulation of these results adds further evidence of the detrimental
effect of smoking on facial appearance in general [30,31].
Our results include examples of the “case-control by proxy” study design, where partici-
pants with relatives who are cases for a given phenotype are used as ‘proxy’ cases and those
with relatives who are controls are used as ‘proxy’ controls [32]. For example, we identified
associations with parental risk of smoking related diseases, such as lung cancer and emphy-
sema, with consistent estimates in ever and never smoking subsamples, likely due to the shared
genetic risk of the UK Biobank participant with their parents. Although we have not identified
examples in our top results, associations may also reflect an effect of the parental genotype of
UK Biobank participants on the phenotype of the UK Biobank participant. For example,
maternal genotype could influence participant’s phenotype via intrauterine exposure to mater-
nal smoking [33].
Our comparison of results across samples demonstrates the value of stratifying to detect
potential causal effects. Of the 12 results identified in our GxE MR-pheWAS (testing interac-
tions), only 5 were identified in our MR-pheWAS using the full sample. While the results of
our MR-pheWAS in the full sample included associations that were not identified in our GxE
MR-pheWAS in ever smokers, such as risk of operative procedures on the tarsometatarsal
joint, and eye problems, these associations may be due to horizontal pleiotropy (or chance)
rather than a causal effect of the smoking heaviness variant through smoking status, as these
associations were consistent in ever and never smokers.
There are some limitations of this work that should be considered. First, while ranking by
interaction strength between ever and never smokers is directly commensurate with our aim
of identifying potential causal effects of smoking heaviness (i.e. outcomes where the effect of
the genetic variant differs among ever versus never smokers), in the presence of horizontal
pleiotropy this has lower statistical power compared with testing for a main effect (e.g. in ever
smokers) and identified only a small number of results. Under the assumption of no horizontal
pleiotropy ranking using the strength of association among ever smokers is a valid approach to
identify interactions and has better statistical power. While this assumption is likely to be vio-
lated for some outcomes, in practice we identified many potentially interesting novel results
with this method, including all but one of the results based on interaction strength. As GxE
MR-pheWAS is a hypothesis-generating approach for discovering potentially interesting asso-
ciations to be further interrogated in independent data, horizontal pleiotropy can be investi-
gated in follow-up analyses. Follow-up is also important because we rank associations from
our MR-pheWAS and GxE MR-pheWAS, such that we should expect the true strength of our
strongest estimates to be less than we reported due to the winner’s curse. We also note that we
test the strength of the interaction by first testing the effect of the SNP on each outcome in ever
and never smokers separately and then following this up with a test for interaction. It is also
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possible to conduct a GxE MR-pheWAS using a model with an interaction term. This would
be essentially equivalent to our stratification approach if the model also includes interactions
between the genetic instrument and all covariates. However, this model approach usually
assumes that the random error (i.e. variance of the error term) is the same across strata.
Second, our approach is based on the assumption that, if smoking heaviness affects an out-
come then we would expect the effect of the genetic variant on the outcome to differ in ever
versus never smokers, illustrated in S6A Fig. However, differing effects in smoking status strata
could be because smoking status (or another factor correlated with smoking status) modifies
the effect of the SNP along a pathway that is not via smoking heaviness. A hypothetical exam-
ple is illustrated in S6D Fig, where the SNP affects drinking heaviness (outcome) via compul-
sive behaviour. In this case the effect of compulsive behaviour on drinking heaviness is
modified by risky behaviour, which also affects smoking status. Thus, the effect of the SNP on
drinking heaviness differs according to risky behaviour and consequently smoking status. GxE
MR results should be considered in conjunction with other evidence from alternative study
designs, as we have done with our facial aging result, to strengthen the evidence through trian-
gulation [30,31]. This issue could also occur if a covariate (e.g. a genetic principal component)
correlates with smoking status and interacts with the SNP, such that researchers using the GxE
MR approach may wish to include interactions between each of the covariates and the SNP in
their models as sensitivity analyses [34]. We also note that, while we focus on horizontal pleiot-
ropy in this study, GxE MR can be used to assess causal effects in the presence of other viola-
tions of the exclusion restriction as long as this violation is the same across strata of the
modifying factor.
Third, UK Biobank is a highly selected sample of the UK population, having a response rate
of 5.5% [35]. For example, UK Biobank participants are, on average, less likely to smoke, and
have less self-reported health conditions, compared with the general population [36]. Among
smokers, the difference between smoking heaviness in UK Biobank compared with the general
population varies by age and sex. For instance, smokers aged 45–54 years in UK Biobank, and
women smokers aged 55–64 years in UK Biobank on average smoke more heavily than those
in the general population, but this difference was not seen among male smokers age 55–64.
Depending on the selection mechanism–i.e. how selection relates to the instrument, exposure
and outcomes variables–estimates of the direct test of association of an instrumental variable
on an outcome may be biased by a particular form of collider bias–selection-induced collider
bias [14,15]. In general, when testing the direct association of an instrument (Z) on an out-
come (Y), collider bias may occur when a third variable (C), or a descendent of C, is condi-
tioned upon in analyses, opening up a non-causal pathway between Z and Y, for example if C
is affected by Y [15]. Other scenarios (i.e. relationships of C with Z, X and Y) that may cause
bias are described by Hughes et al [15]. Selection induced collider bias may occur when vari-
able C (or a descendent of C) represents whether a person is selected into the sample (i.e. when
participation in the study is conditioned upon) [15]. Hence, estimates of association between
two phenotypes–such as our smoking heaviness genetic variant and a given outcome in our
study–may be biased, if either smoking heaviness or the outcome or both affect selection into
the study [15].
Fourth, we found an association between rs16969968 and smoking status, where each addi-
tional smoking-increasing allele of rs16969968 was associated with a 0.98 [95% CI: 0.97, 0.99]
lower odds of being an ever (vs never) smoker. This means that associations may be biased by
selection induced collider bias because we stratify our sample on smoking status. While our
simulations indicated that any collider bias due to the SNP effect on smoking status would
have a negligible impact on the estimated effect of the SNP on a given outcome, it is possible
that this has increased our type 1 error rate (the proportion of null results incorrectly identified
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as ‘hits’) across the large number of tests performed in our MR-pheWAS. Our simulation that
assessed this did show some inflation of the false discovery rate among ever smokers as the
strength of the colliding relationship increased (all false discovery rates were below 0.165 in all
our simulations), but this simulation included strong assumptions. For example, we assumed a
particular relationship between the collider and outcomes (see S2 Fig). It is difficult to estimate
the inflation experienced in our specific phenome scan where confounding structures will vary
across the outcomes tested (see Supplementary section 1). We note also that selection induced
collider bias may also occur if subsets of the population have already died before participating
in UK Biobank or are less likely to participate due to smoking related illness. As smoking
affects risk of death, it may be the case that selection induced collider bias is more extreme in
the ever-smoking subsample, compared to the never-smoking subsample.
Fifth, the estimates used to identify interactions are of the direct association of the genetic
variant with the outcome, and so are not estimates of the magnitude of effect of smoking heavi-
ness. We cannot follow-up results using a formal IV analysis using these UK Biobank data to
estimate a causal effect of smoking heaviness specifically because the association of rs16969968
with smoking heaviness might change across the life-course [37]. For other exposures where
the association of the genetic instrument with the exposure is constant across the life-course,
GxE interactions can be used to estimate the size of causal effects in the presence of horizontal
pleiotropy [38].
Sixth, it is possible that reporting bias of smoking status may have biased associations. For
instance, if some ‘ever’ smokers reported that they have never smoked, then for outcomes
affected by rs16969968 via smoking heaviness the estimate in never smokers would be biased
towards that in ever smokers. This would bias estimates of interaction between ever and never
smokers towards the null. Furthermore, if the effect of smoking heaviness is transient then our
interaction estimates may also be biased towards the null, because previous smokers are
assigned to the ever smoker group but the effect may no longer be present. In this case, testing
the interaction between current (rather than ever) versus never smokers may be the more
appropriate strategy.
Seventh, our GxE MR-pheWAS used a sample of unrelated individuals such that it is possi-
ble associations may be biased due to family structure, for example, by dynastic effects [33].
Where possible, sensitivity analyses should be conducted using cohorts with data on families
such that family structure can be accounted for [33].
Eighth, due to the hypothesis-free nature of a phenome scan, results generated in this way
require careful consideration and follow-up. For example, our MR-pheWAS identified a
potentially interesting association of rs16969968 with risk of diagnosis of the International
Classification of Diseases (ICD) code ‘Descended testis’ (field 41202 value C621). This associa-
tion was found in both ever and never smokers, hence we initially considered whether this
may reflect an effect of parental genotype on offspring phenotype. However, further inspection
revealed that this result is misleading for two reasons. First, this ICD code (C62.1) is a subcate-
gory of ‘Malignant neoplasm of testis’ [C62]), hence pertains specifically to cancerous
descended testis. Second, PHESANT deals with ICD fields by generating a binary variable for
each ICD code, assigning all participants with the code as TRUE and all participants without
the code as FALSE (i.e. assuming no missingness across all participants). This is not appropri-
ate for sex specific codes, where analyses should be restricted to a particular sex. We further
investigated this result by restricting to male participants, and testing the effect of rs16969968
on: 1) ‘malignant neoplasm of testis, descended’ and 2) ‘malignant neoplasm of testis, unspeci-
fied’. The latter serves as a replication for the former, under the assumption that the proportion
of participants with descended versus undescended testis in the ‘unspecified’ group is the same
as the ICD codes (C62.1 versus C62.0) where this is known (i.e. the majority of the unspecified
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group are descended; the ratio in UK Biobank is 1:16). While the positive association with the
‘descended’ group remains in both ever and never smokers (N_descended = 26; odds ratio per
each additional smoking-increasing allele of rs16969968 of 3.52 [95% CI: 2.03, 6.31] in the full
sample), we find little evidence of an association in the unspecified group (N_unspecified = 199;
odds ratio per each additional smoking-increasing allele of rs16969968 of 0.99 [95% CI: 0.80,
1.22] in the full sample), suggesting that the association with the particular outcome is due to
chance.
We used the freely available PHESANT package to search for the presence of causal effects
of smoking heaviness across thousands of outcomes. While we used the rs16969968 SNP as an
instrument for smoking heaviness a recent GWAS (also in UK Biobank) identified 55 smoking
heaviness associated variants which could be used (e.g. combined into an allele score) in future
GxE MR-pheWAS of smoking heaviness [39]. We have shown that the GxE MR-pheWAS is
an effective approach to search for the presence of causal effects of an exposure using observa-
tional data, when the degree to which an exposure manifests is different across known subsets
of the population. While each of the GxE MR and MR-pheWAS approaches have been used
previously, this study is the first that combines these, conducting GxE MR in a hypothesis-free
manner. As in hypothesis-driven GxE studies, this analysis can be used where a phenotype
exists that stratifies the population into two or more groups, with different levels of the expo-
sure. Importantly, the genetic instrument should not be associated with the phenotype used to
stratify the sample, otherwise estimates may be biased due to conditioning on a collider [14].
Other potential applications include searching for the causal effects of alcohol intake (stratified
by never versus ever drinkers), cannabis use (stratified by never versus ever used) and milk
consumption (stratified by never versus ever drinking milk). The interaction can also be quan-
titative. For example, a recent GxE study assessed the effect of BMI on systolic blood pressure,
using Townsend Deprivation index as the ‘interacting’ variable across which the effect of BMI
was expected to vary [38]. This study also demonstrates how GxE can be used to estimate the
size of causal effects in the presence of horizontal pleiotropy by first estimating the horizontal
pleiotropic effect and then using this to improve the causal estimate–hence GxE MR-pheWAS
can be extended to systematically (across many outcomes) estimate the size of causal effects
while accounting for horizontal pleiotropy [38]. We note that estimating the magnitude of a
causal effect requires stronger assumptions compared with testing for the presence of an effect,
such as monotonicity of the effect of the instrument on the exposure [40]. Our approach could
also be applied to qualitative gene by gene interactions. Our study of smoking heaviness serves
as a model for future studies seeking to search for the causal effects of an exposure using GxE
MR-pheWAS. Any potential effects identified by GxE MR-pheWAS need replication in an
independent sample and assessment using other study designs with different sources of poten-
tial bias to strengthen evidence through triangulation [30].
Materials and methods
Study population
UK Biobank is a prospective cohort of 503 325 men and women in the UK aged between 37–
73 years (99.5% were between 40 and 69 years) [41]. This cohort includes a large and diverse
range of data from blood, urine and saliva samples and health and lifestyle questionnaires [42].
Of the 487 406 participants with genetic data, we removed 373 with genetic sex different to
reported sex, and 471 with sex chromosome aneuploidy (identified as putatively carrying sex
chromosome configurations that are not either XX or XY). We found no outliers in heterozy-
gosity and missing rates, which would indicate poor quality of the genotypes. We removed 78
309 participants not of white British ancestry [43]. We removed 73 277 participants who were
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identified as being related, having a kinship coefficient denoting a third degree (or closer)
relatedness [43]. We removed 8 individuals with withdrawn consent, giving a sample of 334
968 participants (we refer to as our full sample). Of these, 182 961 and 150 831 reported being
never and ever (comprising previous and current) smokers, respectively. A participant flow
diagram is given in Fig 6.
Genetic variant for smoking heaviness
Two SNPs in the CHRNA5 gene– rs16969968 and rs1051730 –that are in linkage disequilib-
rium (Pearson’s correlation coefficient = 0.997 in our sample), have been previously shown to
be robustly associated with smoking heaviness via differences in nicotinic receptor function,
and can be used interchangeably in studies of European populations [7]. We use genetic vari-
ant rs16969968 as an instrument for smoking heaviness [17], coded as the number of smoking
heaviness increasing alleles.
Outcomes
The UK Biobank data showcase allows researchers to identify variables based on the field type
(http://biobank.ctsu.ox.ac.uk/showcase/list.cgi). At the time of data download there were 2761
fields of the following types: integer, continuous, categorical (single) and categorical
(multiple).
We excluded 74 fields a priori (see S1 Table) for the following reasons: 1 field denoting the
assessment centre; 2 fields described by UK Biobank as ‘polymorphic’, containing values with
mixed data types; 7 fields that, although listed in the data showcase, were not currently avail-
able; 17 genetic descriptor fields, 1 sex field, 4 age fields, 17 fields describing the assessment
centre environment, 4 data processing indicators, and 21 categorical (single) fields with more
than one value recorded per person.
This resulted in a set of 2687 UK Biobank fields (347 integer, 1392 continuous, 836 categor-
ical [single] and 112 categorical [multiple]), referred to hereafter as the outcome dataset
(because they are tested as an outcome irrespective of whether this is biologically plausible).
Smoking phenotypes
Smoking status was self-reported via a questionnaire at the UK Biobank assessment centre.
Participants were asked to report whether they smoked previously, currently, or whether they
had never smoked. We created a binary variable denoting ever versus never smokers by group-
ing former and current smokers.
Smoking heaviness was derived from the number of cigarettes smoked per day, which was
asked via the same questionnaire, to those who reported being a previous or current smoker.
We categorised the number of cigarettes into four bands: 0–10, 11–20, 21–30 and 31+.
Covariates
We include age and sex as covariates in our models to reduce the variation in our outcomes.
Age when participants attended the UK Biobank assessment centre was derived from their
date of birth and the date of their assessment centre visit. Sex was self-reported during the
touchscreen questionnaire (and validated using the genome-wide data). We adjusted for the
first 10 genetic principal components to control for confounding via population stratification.
Genetic variants are set at conception, and after conception they cannot be affected by factors
that traditionally confound observational associations (such as participant socio-economic
position). Also, while it is possible these factors may be on an alternative confounding pathway
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Fig 6. Participant flow diagram.
https://doi.org/10.1371/journal.pgen.1008353.g006
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between the genetic variant and an outcome (e.g. via parental genotype and parental smoking
heaviness [33]), it is also possible that these factors may be mediators between the participant’s
genetic variant and an outcome, or a collider, such that adjusting for them would induce bias
[44]. Therefore we did not adjust for any further covariates.
Statistical methods
Smoking heaviness genetic variant and self-reported smoking heaviness association.
We tested the association of rs16969968 with smoking heaviness using ordered logistic regres-
sion (ologit Stata command), adjusting for covariates as described above.
PHESANT MR-pheWAS. We searched for the causal effects of smoking heaviness, within
three subsamples of UK Biobank participants: 1) ever smokers, 2) never smokers, and 3) our
full sample. We conducted our MR-pheWAS in two stages. First, we ran PHESANT (version
0.17) with the ‘save’ option, to derive the PHESANT-processed outcomes for all participants in
our full sample. A description of PHESANT’s automated rule-based method is given in detail
elsewhere [23]. In brief, the decision rules start with the variable field type and use rules to cat-
egorize each variable as one of four data types: continuous, ordered categorical, unordered cat-
egorical or binary. Variables with the continuous and integer field type are usually assigned to
the continuous data type, but some are assigned to ordered categorical if, for instance, there
are only a few distinct values. Variables of the categorical (single) field type are assigned to
either the binary, ordered categorical or unordered categorical, depending on whether the
field has two distinct values, or has been specified as ordered or unordered in the PHESANT
setup files. Variables of the categorical (multiple) field type are converted to a set of binary var-
iables, one for each value in the categorical (multiple) fields. An inverse normal rank transform
was applied to variables of the continuous data type, to ensure they were normally distributed.
The derived outcomes were stored in CSV files labelled with the data type, and this informa-
tion was used in the second stage.
In the second stage, for each subsample (ever, never and the full sample), we estimated the
univariate association of rs16969968 with each of the outcome variables derived by PHESANT.
The rs16969968 SNP and outcome are the independent (exposure) and dependent (outcome)
variables in the regression model, respectively. Outcome variables with continuous, binary,
ordered categorical and unordered categorical data types, were tested using linear, logistic,
ordered logistic, and multinomial logistic regression, respectively. All analyses were adjusted
for covariates as described above. The two-stage approach we used ensured that the same data
types were assigned to each outcome across subsamples, as we process and assign data types
using PHESANT on the whole sample. In each stratum, we only test outcomes with (in that
stratum) at least 500 participants and at least 10 participants in each category for binary and
unordered categorical variables.
Identifying results based on strength of interaction of ever versus never smokers. As
described above, we only tested outcomes with more than 500 participants, and with at least 10
participants in each category for binary and unordered categorical variables such that the out-
comes tested in each subsample may vary. For this reason, we first identified the subset of out-
comes tested in both ever and never subsamples (and using the same type of regression). For
this subset, we determined the strength of interaction between ever versus never smokers
using meta regression (metan command in Stata), and ranked the results by the P value of the
generated Q-test statistic–a measure of the heterogeneity across subgroups. We tested interac-
tions of binary and ordered categorical results in terms of the log odds (i.e. the interactions are
assumed to be multiplicative). We corrected for multiple testing by controlling for the
expected proportion of false positive results. We identified the largest rank position with a P
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value less than Pthreshold ¼ 0:05� rank=n, where n is the total number of tests in the phenome
scan. Pthreshold is the P value threshold resulting in a false discovery rate of 5% [45]. We also cal-
culated a highly stringent Bonferroni corrected P value threshold calculated by dividing 0.05
by the number of tests performed, which assumes each test is independent.
Identifying results based on strength of effect in ever smokers. If the genetic variant
affects the outcome via smoking heaviness we would expect (with sufficient statistical power)
to see an effect in ever smokers, except where a horizontal pleiotropic effect of the same magni-
tude in the opposite direction exists–these would cancel out to give a zero total effect. Hence,
we conducted a secondary analysis, ranking outcomes by P value of the estimated effects of
rs16969968 within the ever subsample only. To identify potential causal effects, we used both a
Bonferroni and 5% FDR threshold, as described above. We examined the degree to which hor-
izontal pleiotropy may be biasing results by viewing these estimates alongside the estimates
among never smokers. We also identified top results in our never smoker and full samples, to
compare the sets of results identified using each sample.
It may be reasonable to assume that rs16969968 affects most outcomes only via smoking
heaviness (i.e. there is no horizontal pleiotropy), such that an association between rs16969968
and the outcome in the whole sample would indicate an effect of smoking heaviness on this
outcome. We performed a two-step approach to identify interactions, similar to an approach
for identifying gene-environment interactions proposed previously [46]. First, we ranked out-
comes by the strength of association in the whole sample and used a 5% FDR threshold to
identify results to take forward to step two. Second, we ranked these results by the strength of
interaction between ever and never smokers, ranking by the P value of the Q-test statistic. This
approach is valid because the strength of association in the whole sample is independent of the
strength of the interaction between ever and never smokers.
Follow-up analyses of identified associations. We identified an association with a facial
aging phenotype. Participants were asked ‘do people say you look:’ and asked to select either
‘younger than you are’, ‘about your age’ or ‘older than you are’. It is possible that the PHE-
SANT automated approach made inappropriate decisions in its analysis, hence we re-exam-
ined this association to ensure it is not erroneous. We estimated the effect of rs16969968 on
facial aging, using ordered logistic regression (ologit Stata command), among ever and
never smokers respectively, adjusting for covariates as described above. We also adjusted for
age, sex and the first 40 genetic principal components, as a sensitivity analysis.
We derived a measure of lifetime smoking that incorporates smoking heaviness, duration
and time since cessation into a single measure [47] called the lifetime smoking index as
described previously [48]. We generated a lifetime smoking genetic instrument using the 126
SNPs identified in a recent GWAS of the lifetime smoking index [48]. As this GWAS was also
conducted in UK Biobank, we calculated our lifetime smoking genetic instrument as the sum
of the lifetime smoking index increasing alleles (i.e. we did not weight by the effect size). We
derived a binary measure of facial aging representing whether ‘people say you look older than
you are’ or not, by combining the ‘younger than your age’ and ‘about your age’ categories. We
determined the strength of our lifetime smoking genetic score as an instrument for lifetime
smoking index using linear regression, adjusting for age, sex and the first 10 genetic principal
components. We generated confidence intervals using bootstrapping (with 1000 bootstraps) as
the residuals of this regression (due to non-normality of the lifetime smoking index) were not
normally distributed. We estimated the causal effect of lifetime smoking on facial aging, using
IV probit regression. Again, we generated confidence intervals using bootstrapping (with 1000
bootstraps) as the residuals of the first stage were not normally distributed. We took the expo-
nent of 1.6 times the estimates, to approximate the association in terms of the change of odds
[24].
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Analyses are performed in R version 3.3.1 ATLAS, Matlab r2018a or Stata version 15, and
code is available at [https://github.com/MRCIEU/PHESANT-MR-pheWAS-smoking]. Git tag
v0.4 corresponds to the version presented here.
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S2 Table. Results from smoking heaviness GxE MR-pheWAS below P values threshold of
3:59x10  5with a false discovery rate of 5%, ranked by interaction P value. Total number of
tests with ever and never result, and same regression type = 16692. Bonferroni threshold = 0.05/
16692 = 3.00x10-6. False discovery rate threshold = 0.05x12/16692 = 3.59x10-5. 1 Linear: associa-
tions are the SD difference in inverse rank normal transformed outcome for each additional
smoking-increasing allele of rs16969968. Ordered: Associations are the log odds of a higher out-
come group for each additional smoking-increasing allele of rs16969968. Binary: Associations are
the log odds of comparison versus baseline outcome group for each additional smoking-increas-
ing allele of rs16969968. 2 Strength of interaction between ever versus never smokers using meta
regression (metan command in Stata). 3 Information on categories for multinomial, ordinal and
binary regression results: reference category for multinomial regression results, baseline category
for binary logistic regression results, and category ordering for ordered logistic regression results.
For example, {Younger than you are . . . Older than you are}” for field 1757 means that there are
categories ranging from “Younger than you are” to “Older than you are” where the former is
coded with the smallest value, and the latter with the largest value. 4 In addition to the field ID,
this column also contains the reference value for multinomial regression results, and the field
value for which a binary variable was generated for categorical (multiple) fields.
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S3 Table. Results from smoking heaviness MR-pheWAS below P values threshold of
1.86x10-4 with a false discovery rate of 5%, ranked by P value among ever smokers. Results
of main analysis, adjusting for age, sex and the first 10 genetic principal components. 1 Direc-
tion of change of outcome with genetic predisposition to higher smoking heaviness. 2 For mul-
tinomial logistic regression results a single P value was calculated for each model as a whole,
using the likelihood ratio chi-square test. 3 Information on categories for multinomial, ordinal
and binary regression results: reference category for multinomial regression results, baseline
category for binary logistic regression results, and category ordering for ordered logistic
regression results. For example, “{thinner . . . plumper}” for field 1687 means that there are cat-
egories ranging from thinner to plumper where thinner is coded with the smallest value and
plumper with the largest value. 4 In addition to the field ID, this column also contains the ref-
erence value for multinomial regression results, and the field value for which a binary variable
was generated for categorical (multiple) fields. 5 Where test type differs in never smokers this
is shown in brackets. Bonferroni threshold = 2.70x10-6 (0.05/18513); false discovery rate
threshold = 0.05x69/18513 = 1.86x10-4. Binary, linear and ordered results in this table are
shown in Figs 3–5 in main paper (one result was an unordered categorical result [Field 1448
reference 3], and is not shown as P value was generated using a likelihood ratio test such that
an estimate and confidence interval is not available).
(PDF)
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S4 Table. Results from smoking heaviness MR-pheWAS below P values threshold of
2:23x10  5with a false discovery rate of 5%, ranked by P value among never smokers. Total
number of tests in never smokers = 17975. Bonferroni threshold = 0.05/17975 = 2.78x10-6.
False discovery rate threshold = 0.05x8/17975 = 2.23x10-5.
(PDF)
S5 Table. Results from smoking heaviness MR-pheWAS below P values threshold of
1.04x10-4 with a false discovery rate of 5%, ranked by P value among all participants. Total
number of tests in whole sample = 23009. Bonferroni threshold = 0.05/23009 = 2.17x10-6.
False discovery rate threshold = 0.05x48/23009 = 1.04x10-4.
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S6 Table. Results from smoking heaviness MR-pheWAS using two-step approach. Step 1:
Rank results by association strength among whole sample, identifies 48 results (S4 Table), of
which 36 have an interaction P value for use in step 2. Step 2: Rank results by strength of inter-
action of ever versus never smokers. Bonferroni threshold = 0.05/36 = 1.39x10-3. False discov-
ery rate threshold = 0.05x9/36 = 1.25x10-2. 1 Linear: associations are the SD difference in
inverse rank normal transformed outcome for each additional smoking-increasing allele of
rs16969968. Ordered: Associations are the log odds of a higher outcome group for each addi-
tional smoking-increasing allele of rs16969968. Binary: Associations are the log odds of com-
parison versus baseline outcome group for each additional smoking-increasing allele of
rs16969968. 2 Strength of interaction between ever versus never smokers using meta regression
(metan command in Stata). 3 Information on categories for multinomial, ordinal and binary
regression results: reference category for multinomial regression results, baseline category for
binary logistic regression results, and category ordering for ordered logistic regression results.
For example, {Younger than you are . . . Older than you are}” for field 1757 means that there
are categories ranging from “Younger than you are” to “Older than you are” where the former
is coded with the smallest value, and the latter with the largest value. 4 In addition to the field
ID, this column also contains the reference value for multinomial regression results, and the
field value for which a binary variable was generated for categorical (multiple) fields.
(PDF)
S1 Fig. Overlap of ‘top’ results across our MR-pheWAS analyses in ever smokers, never
smokers and the full sample, and our GxE MR-pheWAS ranking based on interaction
strength.
(PDF)
S2 Fig. Illustration of simulated collider bias. In our UK Biobank sample the smoking heavi-
ness genetic variant is estimated to affect both smoking status and the identified outcome phe-
notypes. If a confounder exists that affects both smoking status and a given outcome then
smoking status is a collider and stratifying on smoking status may cause collider bias–bias in
the estimated effect of the genetic variant on the outcome phenotype. An exception to this is
when the genetic variant for smoking heaviness does not affect the outcome, and they act addi-
tively on smoking status (i.e. there is no additive interaction on the log-probability scale). In
this case, collider bias would not occur.
(PDF)
S3 Fig. Results of collider bias simulations of facial aging, with range of effect sizes of con-
founder on outcome. ORconf,si is the odds ratio of the confounder on smoking status, i.e. the
change of odds of being an ever versus never smoker for a 1 standard deviation increase in con-
founder. r2 is proportion of the variance of the continuous facial aging phenotype (underlying
MR-pheWAS with stratification and interaction: Searching for the causal effects of smoking heaviness
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the categorical facial aging outcome) that is explained by the confounder. a-d: positive effect of
confounder on outcome, with OR of the confounder on smoking status of 10 (a), 20 (b), 50 (c)
and 100 (d). e-h: negative effect of confounder on outcome, with OR of the confounder on
smoking status of 10 (e), 20 (f), 50 (g) and 100 (h).
(PDF)
S4 Fig. Results of collider bias simulation of continuous outcome, with range of effect sizes
of confounder on outcome. ORconf,si is the odds ratio of the confounder on smoking status,
i.e. that change of odds of being an ever versus never smoker for a 1 standard deviation
increase in confounder. r2 is proportion of the variance of the continuous phenotype that is
explained by the confounder. a-d: positive effect of confounder on outcome, with OR of the
confounder on smoking status of 10 (a), 20 (b), 50 (c) and 100 (d). e-h: negative effect of con-
founder on outcome, with OR of the confounder on smoking status of 10 (e), 20 (f), 50 (g) and
100 (h).
(PDF)
S5 Fig. Illustration of bias when SNP has a greater effect on smoking status compared with
the effect seen in UK Biobank. These simulations assume a large (and hence unlikely) effect
of the confounder on smoking status (odds ratio = 100; i.e. we are assuming a 1 standard devia-
tion change of the confounder causes a 100 higher odds of being an ever smoker). Further-
more, we assume a 1 dosage increase in SNP causes a 0.8 lower odds of being an ever smoker
(i.e. we have made this more extreme than we see in UK Biobank for illustration purposes). (a)
Categorical facial aging outcome, positive effect of confounder on outcome. (b) Continuous
outcome, positive effect of confounder on outcome. (c) Categorical facial aging outcome, neg-
ative effect of confounder on outcome. (d) Continuous outcome, negative effect of confounder
on outcome. In plots (a) and (c) r2 is proportion of the variance of the continuous facial aging
phenotype (underlying the categorical facial aging outcome) that is explained by the con-
founder. In plots (b) and (d) r2 is proportion of the variance of the continuous phenotype that
is explained by the confounder.
(PDF)
S6 Fig. Illustration of pathways that do and do not cause an interaction due to smoking
status. Solid black boxes indicate an interaction. Box around smoking status variable indicates
that this variable is conditioned upon (i.e. we stratify on ever versus never smokers). Please see
code in the project’s GitHub repository [http://github.com/MRCIEU/PHESANT-MR-
pheWAS-smoking/] for simulations of these scenarios. a) Our hypothesised pathway, where
the genetic variant affects the outcome via smoking heaviness. b) Independent effects of the
SNP and smoking status on the outcome are not problematic–the effect estimates in smoking
status strata (ever versus never) are still consistent. c) If there is only an effect on the outcome
via smoking status, rather than smoking heaviness, then within smoking status strata there is
no association between the SNP and the outcome. d) An interaction of smoking status along
the pathway between the SNP and outcome would also give an interaction of the effects of the
SNP across smoking status strata.
(PDF)
S7 Fig. Example violation of exclusion restriction assumption that is not horizontal pleiot-
ropy, but for which GxE MR can be used to identify causal effects. In this figure we show
two directed acyclic graphs (DAGs), after stratification by ever versus never smokers (of the UK
Biobank participants). We assume an effect of parental smoking heaviness on the UK Biobank
participants outcome. This alternative pathway between the UK Biobank participant’s SNP and
the outcome (via parental SNP and parental smoking heaviness) is the same in UK Biobank
MR-pheWAS with stratification and interaction: Searching for the causal effects of smoking heaviness
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ever and never smokers. It is not horizontal pleiotropy because there is no causal effect of the
SNP (or more precisely the genetic variation for which the SNP is tagging) on the outcome–it is
the parental genetic variation that affects the outcome. Note also that this assumes participant
smoking status is independent of parental smoking status, otherwise the extent to which this
alternative pathway manifests would vary in UK Biobank participant ever versus never smok-
ers.
(PDF)
S1 File. Results from smoking heaviness MR-pheWAS.
(TSV)
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